Get the Stockscreener App
3.01
2.90%
-0.09
After Hours:
3.01
Lipocine Inc stock is traded at $3.01, with a volume of 8,217.
It is down -2.90% in the last 24 hours and down -1.95% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$3.10
Open:
$2.95
24h Volume:
8,217
Relative Volume:
0.36
Market Cap:
$16.10M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.9869
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-8.23%
1M Performance:
-1.95%
6M Performance:
-35.41%
1Y Performance:
-34.71%
1-Day Range:
$2.95
$3.3199
1-Week Range:
$2.95
$3.57
52-Week Range:
$2.95
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.01 | 16.10M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc. Reports 2024 Financial Turnaround - TipRanks
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase - Stock Titan
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss Formula - GlobeNewswire Inc.
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Lipocine announces FDA labeling changes for testosterone products - TipRanks
FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa
LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK
Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Armenian Reporter
Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World
Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World
Lipocine plans phase 3 study for postpartum depression drug - MSN
Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com
Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal
Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World
(LPCN) On The My Stocks Page - Stock Traders Daily
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
FDA fast tracks Lipocine's sarcopenia treatment - Investing.com
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire
FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online
Where are the Opportunities in (LPCN) - Stock Traders Daily
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):